Loss of Taste and Smell Sensation in COVID-19: A Questionnaire Based Multicontinental Study with Review

Fatema Akhter a*, Mohammed Malik Afroz a#,¥, Tahsinul Haque b#,¥, Khetam Alarady c*, Agharid Fouad Al Yaqoub c#, and Ghadh Salim Abu Salim d‡

a Department of Surgical and Diagnostic Sciences, College of Dentistry, Dar Al Uloom University, Saudi Arabia.
b Department of Preventive Dental Sciences, College of Dentistry, Dar Al Uloom University, Saudi Arabia.
c College of Dentistry, Dar Al Uloom University, Saudi Arabia.
d Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin AbdulAziz University, Saudi Arabia.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2022/v34i50A36432

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/71061

Received 15 February 2022
Accepted 11 April 2022
Published 09 September 2022

ABSTRACT

Introduction: Taste buds are the peripheral organs of gustation and are located mainly in the tongue epithelium and palate. Taste buds further sample the chemical makeup of foods and beverages for nutrient content, palatability, and potential toxicity. On the other hand, the smell acts as a major factor and mostly functions involuntarily thereby identify chemical makeup and protecting from potential toxic insult. The coronavirus disease 2019 (COVID-19) is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world. An important highlight is an atypical new presentation of the disease: patients with olfactory and gustatory dysfunctions.
Objectives: To know whether the loss of taste and smell are a reliable symptomatic indicator in early diagnosis of COVID as well as how it impacts on the nutrition and early patient’s recovery.

Results: A questionnaire originally developed by AAO – NHS (American academy of otolaryngology neck and head surgery) was modified to include the questions related to loss of taste. We have included a total of 512 patient of which 82.4% were females. The common risk factor reported by our patients was close contact with a potentially confirmed case which accounted for 46.1%. The common comorbidities reported in the population has largely been related to breathing problems in the form of asthma 10.2%, sinus and smoking allergies of 5.7% which is a known factor in the spread of Covid in these patients. We have noticed in our population that there was a loss of smell and taste noticed in all the subjects and among them 66.5% reported with anosmia and 52.3% reported with ageusia which was either overlooked or not understood by most of the patients. Hyposmia and Parosmia was 18.6% and 14.9% respectively while Hypogeusia and dygeusia was 32.2% and 15.4% indicating that though complete loss of taste is less when compared to complete loss of smell but alteration in taste is much higher and was felt for a much longer duration of time and often reported but complete remission from loss of taste is not completed.

Conclusion: Loss of smell and taste should be considered as one of the reliable symptomatic indicators to covid infection and an active attempt should be made for its early remission for the patients to return back to normal intake of food leading to adequate nutrient supply

Keywords: Taste sensation; smell sensation; COVID-19; viral pandemic; symptomatic relief.

1. INTRODUCTION

Taste buds are the peripheral organs of gustation and are located mainly in the tongue epithelium and palate. Taste buds sample the chemical makeup of foods and beverages for nutrient content, palatability, and potential toxicity. The substantial diversity and redundancy of the molecular receptors for the food compounds may reflect the importance of identifying nutrients and avoiding chemical threats from the environment. The molecular recognition of tastants, which occurs at the apical tips of taste bud cells, ultimately results in sensory perceptions (for example, sweet, salty, and so on) that guide appetite and trigger physiological processes for absorbing nutrients and adjusting metabolism [1]. On the other hand, the smell acts as a major factor and mostly functions involuntarily thereby identify chemical makeup and protecting from potential toxic insult. The coronavirus disease 2019 (COVID-19) is an ongoing viral pandemic that emerged from East Asia and quickly spread to the rest of the world [1]. This infection is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. The most prevalent symptoms consist of fever, cough, dyspnea, sputum production, myalgia, arthralgia, headache, diarrhea, rhinorrhea, and sore throat [3,4]. An important highlight is an atypical new presentation of the disease: patients with olfactory and gustatory dysfunctions. The occurrence of smell dysfunction in viral infections is not new in otolaryngology. Many viruses may lead to olfactory dysfunction (OD) through an inflammatory reaction of the nasal mucosa and the development of rhinorrhea; the most familiar agents being rhinovirus, parainfluenza, Epstein–Barr virus, and some coronavirus [5,6]. However, olfactory dysfunction linked to COVID19 infection seems as it is not associated with rhinorrhea. In a similar way lot of patients have also reported complete loss of taste sensation much before the arrival of identifiable symptoms [7]. Initially the patients as well as the doctors attending them overlooked it, since it was not reported as a possible symptom by the patient and neither it was recorded by the attending doctors as reported in literature [7,8,9]. The initial objective mode of transmission of coronavirus included even surface and aerosol transmission which has stopped the dental treatment for quite some time but the symptoms of loss of taste and smell has gained a lot importance to be taken seriously as it is believed to be first sign even in the absence of objective symptoms.

2. MATERIALS AND METHODS

A questionnaire originally developed by AAO – NHS (Amarecan academy of oto – laryngeology neck and head surgery) has questions related to loss of smell which was modified in this study to include the questions related to loss of taste. The original AAO – NHS tool was developed by 2 committees of the AAO-HNS: the Infectious Disease and Patient Safety Quality Improvement committees. The tool is completed online either by the medical provider or the patient and
consists of 17 questions relating to demographic factors, COVID status, risk factors, symptoms, and onset of anosmia/dysgeusia and so on and may be found at https://www.entnet.org/content/reporting-tool-patients-anosmia-related-covid-19. This anosmia reporting tool collects data to establish the importance of smell and taste impairment in the clinical course of COVID-19. We have modified this tool and added questions to it thereby taking the total count of questions in the questionnaire to be 33 (Table 1). We also had a systematic review of articles from the MEDLINE, Embase and Global Health, also Web of Science and Scopus including pre-prints from the year 2019 December to May 2021.

2.1 Patient Selection

We have enrolled 512 patients who were diagnosed with COVID and fully recovered from it, through a database of COVID prescribed hospitals in Saudi Arabia. In Saudi Arabia all the citizens were allowed to go for a free PCR testing even with minor symptoms of fever and cough. After collecting the database, these patients were contacted through telephonic conversation and after each patient’s approval the questionnaire was filled by 3 independent reviewers who are well versed with the spoken language in the Saudi Arabia. To avoid confusion, we have enrolled only those patients who were diagnosed with covid PCR report.

2.2 Inclusion Criteria

All the patients who will be having loss of taste and / or smell sensation during their phase of COVID-19 infection. All the patients were more than 18 years. Both male and female patients who can recollect and give exact information were included. A total of 600 patients were contacted, out of which 512 patients cooperated and recollected the symptoms of loss of taste and smell during their infection due to coronavirus.

2.3 Exclusion Criteria

Those patients who have recovered from COVID 19 but never experienced or are not able to recall the loss of taste and / or smell sensation, out of total 600 patients, 50 were not able to recollect the symptoms of loss of taste and smell while 38 patients confirmed that there was no loss of taste or smell experienced by them.

Table 1. Questionnaire used to evaluate COVID-19 positive subjects (Adopted from the American Academy of Otolaryngology-Head and Neck Surgery COVID-19 anosmia reporting tool)

| Questions                                                                 | Please indicate the answer here                                                                 |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Q1. Name/Surname                                                          |                                                                                                 |
| Q2. Phone/e-mail address                                                  |                                                                                                 |
| Q3. Age (numbers)                                                         |                                                                                                 |
| Q4. Gender                                                                | Female                                              Male                                                                                     |
| Q5. Please list any risk factors for COVID-19                             | None                                                Healthcare worker                                                                                 |
|                                                                           | Close contact with a confirmed case                                                             |
|                                                                           | Homeless                                                                                         |
|                                                                           | Congregant living (dorms, fraternities/sororities, shelters, jail, prison, skilled nursing, assisted |
|                                                                           | living, adult family home)                                                                      |
|                                                                           | Travel to known areas with widespread community transmission                                   |
|                                                                           | Other                                                                                           |
| Q6. Other risk factors/comorbidities                                      | None                                                Smoking                                                                                         |
|                                                                           | Head trauma                                                                                      |
|                                                                           | Sinusitis/allergy                                                                                |
|                                                                           | Chronic respiratory disease/Asthma                                                              |
|                                                                           | Cardiac disease                                                                                  |
|                                                                           | Neurologic disease (e.g. Parkinson’s)                                                           |
|                                                                           | Other                                                                                           |
| Q7. Complaints when the sample is received from the patients              | None                                                Fever                                                                                         |
|                                                                           | Chills                                                                                            |
### Questions

| Questions                                                                 | Please indicate the answer here |
|---------------------------------------------------------------------------|---------------------------------|
| (this will be excluded as ours is a retrospective study)                   | • Malaise                        |
| • Cough                                                                   | • Headache                       |
| • Nasal congestion                                                        | • Rhinorrhea                     |
| • Gastrointestinal distress                                               | • Pneumonia                      |
| • Other                                                                   |                                 |
| Q8. Is the source of the COVID-19 infection identifiable?                  | • Yes                            |
| • No                                                                      |                                 |
| Q9. What is the patient's current COVID-19 infection status? (will be     | • Active                         |
| removed as ours is a retrospective study)                                 | • Recovered                      |
| Q10. Did the patient receive treatment?                                   | • Yes                            |
| • No                                                                      |                                 |
| Q11. Did the patient have smell/taste impairment?                         | • Yes                            |
| • No                                                                      |                                 |
| Q12. Definition of smell impairment (if present)                           | • Anosmia                        |
| • Hyposmia                                                                | • Parosmia                       |
| Q12a. Please indicate the degree of hyposmia on 10 scale VAS (indicate    | 0 1 2 3 4 5 6 7 8 9 10           |
| number) (10 indicate normal)                                              |                                 |
| Q13. Definition of taste impairment (if present)                          | • Ageusia                        |
| • Hypogeusia                                                              | • Dysgeusia                      |
| Q13a. Please indicate the degree of hypogeusia on 10 scale VAS (indicate  | 0 1 2 3 4 5 6 7 8 9 10           |
| number) (10 indicate normal)                                              |                                 |
| Q14. What was the condition of the COVID-19 infection at the time the    | • Inpatient /hospitalized        |
| smell/taste impairment was observed?                                      | • Outpatient                     |
| Q15. When was the smell/taste impairment first noticed by the patient    | • Before diagnosis               |
| • After diagnosis                                                        |                                 |
| Q16. Did the patient have any other symptoms before the development of   | • Yes                            |
| smell/taste impairment?                                                   | • No                             |
| Q17. What symptoms did the patient have at the time of smell/taste        | • None                           |
| impairment?                                                               | • Fever                          |
| • Chills                                                                  | • Malaise                        |
| • Cough                                                                   | • Headache                       |
| • Nasal congestion                                                        | • Rhinorrhea                     |
| • Gastrointestinal distress                                               | • Pneumonia                      |
| • Other                                                                   | • Other                          |
| Q18. Did the patient’s condition worsen or improve after the smell/taste | • Worsen                         |
| impairment was observed?                                                  | • Improve                        |
| Q19. Did the smell/taste impairment resolve?                              | • Yes                            |
| • No                                                                      |                                 |
| Additional Questions                                                      |                                 |

| Questions                                                                 | Please indicate the answer here |
|---------------------------------------------------------------------------|---------------------------------|
| Q20 Was there any change in the salivation noticed                        | • Yes                            |
| • No                                                                      |                                 |
| Q21. What symptoms did the patient have at the time of salivation change? | • None                           |
| • Fever                                                                   | • Chills                         |
| Questions                                                                 | Please indicate the answer here                                      |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                           | • Malaise                                                              |
|                                                                           | • Cough                                                                |
|                                                                           | • Headache                                                             |
|                                                                           | • Nasal congestion                                                     |
|                                                                           | • Rhinorrhea                                                          |
|                                                                           | • Gastrointestinal distress                                            |
|                                                                           | • Pneumonia                                                           |
|                                                                           | • Other                                                                |
| Q22 Definition of change in salivation                                  | • Over salivation – watery/turbid                                     |
|                                                                           | • Under salivation – ropy/dryness                                     |
| Q23. Did the patient’s condition worsen or improve after the smell/taste| • Worsen                                                              |
| impairment was observed                                                  | • Improve                                                             |
| Q24. Was there any burning sensation noticed in the by the patient      | • Yes                                                                 |
|                                                                           | • No                                                                  |
| Q25. What symptoms did the patient have at the time of burning sensation?| • None                                                                |
|                                                                           | • Fever                                                                |
|                                                                           | • Chills                                                               |
|                                                                           | • Malaise                                                              |
|                                                                           | • Cough                                                                |
|                                                                           | • Headache                                                             |
|                                                                           | • Nasal congestion                                                     |
|                                                                           | • Rhinorrhea                                                          |
|                                                                           | • Gastrointestinal distress                                            |
|                                                                           | • Pneumonia                                                           |
|                                                                           | • Other                                                                |
| Q26 Was there any other symptoms noticed by the patient                 | • Bad odor                                                            |
|                                                                           | • Bleeding gums                                                       |
|                                                                           | • Any other                                                           |
| Q27. What symptoms did the patient have at the time symptoms?           | • None                                                                |
|                                                                           | • Fever                                                                |
|                                                                           | • Chills                                                               |
|                                                                           | • Malaise                                                              |
|                                                                           | • Cough                                                                |
|                                                                           | • Headache                                                             |
|                                                                           | • Nasal congestion                                                     |
|                                                                           | • Rhinorrhea                                                          |
|                                                                           | • Gastrointestinal distress                                            |
|                                                                           | • Pneumonia                                                           |
|                                                                           | • Other                                                                |
| Q28 Has the symptoms resolved                                           | • Yes                                                                 |
|                                                                           | • No                                                                  |
| Q29 Were these symptoms described to the physician                      | • Yes                                                                 |
|                                                                           | • No                                                                  |
| Q30 Is the patient aware of what treatment was given by the physician   | • None                                                                |
| was given by the physician towards the said complaint                    | • Verbal assurance                                                    |
|                                                                           | • Medications                                                         |
|                                                                           | • Oral application                                                    |
|                                                                           | • Any other                                                           |
| Q31 Were the symptoms resolved following the treatment                  | • Yes                                                                 |
|                                                                           | • No                                                                  |

### 3. RESULTS

We have included a total of 512 patients, most of our patients happened to be females which accounted for about 82.4% suggesting that more females were affected than the males. The common risk factor reported by our patients was close contact with a potentially confirmed case which accounted for 46.1% followed by coming in contact with a suspected case while in
congregation which was 13.1% (Table 2) suggesting that the initial response of the population towards understanding the spread of infection was less which gradually increased primarily due to governments active mass awareness programmes and strict follow up of the protocol where mass gathering were avoided which had a great effect in controlling spread of infection. The common comorbidities reported in the population has largely been related to breathing problems in the form of asthma 10.2%, sinus and smoking allergies of 5.7% which is a known factor in the spread of Covid in these patients (Table 3). Most of the population about 56.3% were able to identify the symptoms of the infection and reported themselves for screening indicating the success of mass awareness carried out by the government authorities. About 71.1% were admitted to the hospital which is again suggestive of the governments readiness in providing the treatment to the population and secondly lack of social stigma which made the patients to come forward at the very early stage which reduced the mortality rate drastically. We have noticed in our population that there was a loss of smell and taste noticed in all the subjects and among them 66.5% reported with anosmia and 52.3% reported with ageusia which was either overlooked by the doctors treating these patients or was not considered as a relevant symptom by most of the patients. Hyposmia and Parosmia was 18.6% and 14.9% respectively (Table 4) suggesting that decrease in smell sensation is more rather than altered smell sensation while Hypogeusia and dysgeusia was 32.2% and 15.4% (Table 5) indicating that though complete loss of taste is less when compared to complete loss of smell but alteration in taste is much higher and was felt for a much longer duration of time, as our patients still suffered with these symptoms even during the time of writing this article. Hence, we can believe that though the loss of smell sensation may be an initial sign and loss of taste, or its alteration is a more prolonged process with patients still suffering even after all the known symptoms have subsided. Most patients noticed the loss of taste and smell as secondary to other symptoms like fever which accounted for 52.7%, nevertheless about 47.3% patients noticed loss of taste and smell after being diagnosed of covid through PCR test which suggests that the awareness to acknowledge the loss of taste and smell as a symptom to covid is lacking. After the identification of loss of taste and smell symptom, the condition of the patient was

| List any risk factors for COVID-19 infection present | Frequency | Percent |
|---------------------------------------------------|-----------|---------|
| Close space contact                               | 11        | 2.1     |
| Close contact with a confirmed case,              | 236       | 46.1    |
| Close contact with a confirmed case, Congregant   | 67        | 13.1    |
| Close contact with a confirmed case, Within home, | 3         | 0.6     |
| Close contact with a confirmed case, Outside home (relative) | 6 | 1.2 |
| Close contact with a confirmed case, Outside Home (during travel) | 5 | 1 |
| Close contact with a confirmed case, Travel to k | 41        | 8       |
| Close contact with a confirmed case, Travel to kn | 1         | 0.2     |
| Close contact with a confirmed case, Congregant li | 1        | 0.2     |
| Close contact with a confirmed case, Congregant living | 1 | 0.2 |
| Congregant living (e.g. dorms),                   | 3         | 0.6     |
| Congregant living (e.g. dorms), Travel to known ar | 2        | 0.4     |
| Healthcare worker                                 | 15        | 2.9     |
| Healthcare worker, Close contact with a confirmed | 45        | 8.8     |
| Healthcare worker, Congregant living (e.g. dorms), | 7         | 1.4     |
| Healthcare worker, Homeless, Travel to known areas | 1       | 0.2     |
| Healthcare worker, Travel to known areas with wide exposure | 1 | 0.2 |
| Homeless person (having no shelter)               | 2         | 0.4     |
| Homeless, Congregant living (e.g. dorms),         | 1         | 0.2     |
| None                                              | 51        | 10      |
| None Close contact with a confirmed case,         | 1         | 0.2     |
| None Close contact with a confirmed case, while Travel | 1  | 0.2 |
| Travel to known areas with widespread community exposure | 9 | 1.8 |
| Works in grossary store                           | 1         | 0.2     |

Total 512 100
Table 3. Study population with known comorbidities

| Comorbidities | Frequency | Percent |
|---------------|-----------|---------|
| Cardiac disease, | 5 | 1 |
| Cardiac disease, Neurologic disease (e.g. Parkinson) | 1 | 0.2 |
| Chronic respiratory disease, Asthma, | 52 | 10.2 |
| Chronic respiratory disease, Asthma, Cardiac disease | 23 | 4.5 |
| Chronic respiratory disease, Asthma, Neurologic disease | 4 | 0.8 |
| Head trauma | 1 | 0.2 |
| Head trauma, | 9 | 1.8 |
| Head trauma, Chronic respiratory disease, Asthma, | 2 | 0.4 |
| Head trauma, Chronic respiratory disease, Asthma, Ca | 3 | 0.6 |
| Head trauma, Chronic respiratory disease, Asthma, Neurologic disease | 1 | 0.2 |
| Head trauma, Sinusitis, allergy, | 6 | 1.2 |
| Head trauma, Sinusitis, allergy, Chronic respiratory disease, Asthma | 15 | 2.9 |
| Head trauma, Sinusitis, allergy, Neurologic disease | 2 | 0.4 |
| Neurologic disease (e.g. Parkinsonism) | 2 | 0.4 |
| None | 165 | 32.2 |
| Sinusitis, allergy, | 59 | 11.5 |
| Sinusitis, allergy, Cardiac disease, Neurologic disease | 1 | 0.2 |
| Sinusitis, allergy, Chronic respiratory disease, Asthma | 57 | 11.1 |
| Sinusitis, allergy, Neurologic disease (e.g. Parkinsonism) | 4 | 0.8 |
| Smoking, | 12 | 2.3 |
| Smoking, Cardiac disease, | 1 | 0.2 |
| Smoking, Chronic respiratory disease, Asthma | 1 | 0.2 |
| Smoking, Chronic respiratory disease, Asthma, | 17 | 3.3 |
| Smoking, Chronic respiratory disease, Asthma, Cardiac | 19 | 3.7 |
| Smoking, Chronic respiratory disease, Asthma, Neurologic disease | 1 | 0.2 |
| Smoking, Head trauma, Chronic respiratory disease | 2 | 0.4 |
| Smoking, Head trauma, Sinusitis, allergy, Chronic respiratory disease | 3 | 0.6 |
| Smoking, Sinusitis, allergy, | 6 | 1.2 |
| Smoking, Sinusitis, allergy, Cardiac disease | 1 | 0.2 |
| Smoking, Sinusitis, allergy, Chronic respiratory disease | 29 | 5.7 |
| Total | 512 | 100 |

Table 4. Loss of smell sensation

| Definition of smell impairment | Frequency | Percent |
|-------------------------------|-----------|---------|
| Anosmia | 339 | 66.5 |
| Hyposmia | 95 | 18.6 |
| Parosmia | 76 | 14.9 |
| Total | 510 | 100 |

Table 5. Loss of taste sensation

| Definition of taste impairment | Frequency | Percent |
|-------------------------------|-----------|---------|
| Ageua | 268 | 52.3 |
| Hypogeua | 165 | 32.2 |
| Dysgeua | 79 | 15.4 |
| Total | 512 | 100 |

more worsened as reported by 82.8% and about 73.4% patients still have not recovered fully from the loss of taste and smell sensation as the case of hypogeua and dysgeua is higher when compared to hyposmia and parosmia. Most of the patients were still under vitamin and nutrient supplements since their appetite has reduced and they blame it largely to the altered taste sensation.

4. DISCUSSION

According to recent research, similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is zoonotic, with Chinese horseshoe bats (Rhinolophus sinicus) being the most probable origin as per Chan et al. 2020; Lu et al. 2020 [10] and pangolins as the most likely intermediate host (The Chinese Preventive Medicine...
Based on findings of genetic and epidemiologic research, it appears that the COVID-19 outbreak started with a single animal-to-human transmission, followed by sustained human-to-human spread (Chan et al. 2020; Del Rio and Malani 2020) [12]. Although patients with symptomatic COVID-19 have been the main source of transmission, recent observations suggest that asymptomatic patients and patients in their incubation period are also carriers of SARS-CoV-2 (Chan et al. 2020; Rothe et al. 2020) [13].

This epidemiologic feature of COVID-19 has made its control extremely challenging, as it is difficult to identify and quarantine these patients in time, which can result in an accumulation of SARS-CoV-2 in communities (The Chinese Preventive Medicine Association 2020) [14,15]. There has been various questionnaires used now and even before for identification of loss of smell for other diseases like influenza, rhinovirus, parainfluenza Epstein–Barr virus, and some coronavirus. Well fabricated questionnaire has been of The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS). The acceptance of this was due to a result of cumulative anecdotal evidence of anosmia/dysgeusia around the world during the outbreak, the COVID-19 Anosmia Reporting Tool was developed in March 2020 by the AAO-HNS [10]. This tool was developed by 2 committees of the AAO-HNS: the Infectious Disease and Patient Safety Quality Improvement committees. The tool is completed online either by the medical provider or the patient and consists of 17 questions relating to demographic factors, COVID status, risk factors, symptoms, and onset of anosmia/dysgeusia and so on and may be found at https://www.entnet.org/content/reporting-tool-patients-anosmiarelated-covid-19. This anosmia reporting tool collects data to establish the importance of smell and taste impairment in the clinical course of COVID-19. For this purpose, we used the tool and conducted a comparative study with COVID-19–negative subjects. Further, the study conducted by Ibrahim Sayin added supplemental questions by adding separate questions for Anosmia and dysgusia. These supplemental questions were included in our study which included 17 questions, with 1 question asking about both anosmia and dysgeusia. This helped in obtaining more data from the subjects [10]. As evident through our study it was proven beyond doubt that coronavirus spread through person–person contact by respiratory spread and the initial response of the governments in making the mouth mask as a compulsion was a correct move [16,17,18,19]. The common comorbidities

Fig. 1. Response of Patients to Complete resolution of Loss of Taste / Smell Impairment

| DID THE SMELL/TASTE IMPAIRMENT RESOLVE? |
|-----------------------------------------|
| YES                                   | 75.4 |
| NO                                    | 24.6 |

Table: Response of Patients to Complete resolution of Loss of Taste / Smell Impairment

| DID THE SMELL/TASTE IMPAIRMENT RESOLVE? | YES | NO |
|-----------------------------------------|-----|----|
| YES                                     | 75.4|    |
| NO                                      | 24.6|    |
associated with covid infection were people with other respiratory complications like asthma, sinusitis, upper respiratory infection and the habit of smoking which was seen in other populations as well to an extent that patients losing the taste to smoking leading to its withdrawal by themselves [19,20]. Other comorbidities like cardiac diseases were reported to cause less effect as there was no direct relation of COVID in patients who were under ACE inhibitors was reported in our study. This can be related to most of the patients having multiple comorbidities rather than cardiac alone. In our population loss of smell was reported more than the loss of taste. Even in them a complete loss of taste and smell is higher than the alteration in either smell or taste which is seen even in other populations [21,22,23]. The resumption of smell was faster and complete in many of our patients, but the loss of taste still continues to worry some of the patients but however the complete loss of taste has changed itself into altered taste sensation rather than complete loss. This has been the case in other populations around the world [22,23]. This loss of taste has taken longer time to get recovered from the covid infection as altered taste has caused them reduced diet leading to inadequate nutrition which has further caused dependability of patients to medications rather than gaining sufficient nutrient supply through diet [24,25].

5. CONCLUSION

It has been noticed through our study that in the early stages of covid progression the community was at large callous to adhere to the COVID norms which has caused the spread of infection to a pandemic stage and only after the WHO declared it to be pandemic the governments were able to put up guidelines and it was only through the strict adherence of the guidelines the populations were protected. In our population, mass education was provided to all, and efficient application of guidelines helped in maintaining the infected persons rate low. Secondly the patients have voluntarily come forward for the treatment and the government was able to provide complete health support leading to lesser death rate compared to many countries. Lastly the lack of taste and smell sensation should be considered as an important symptom as it can affect the patient’s ability to take up high nutrient food [24,25] which can lead to early remission and ability to fight with the infection. Our questionnaire can be used to ascertain the symptoms of loss of taste and smell and further follow up of the progress in the symptom’s remission.

CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

This study is being conducted in the Dar al Uloom university after obtaining ethical clearance from its ethical committee.

ACKNOWLEDGEMENT

The authors extend their appreciation to the Deanship of Postgraduate and Scientific Research at Dar Al Uloom University, Riyadh, KSA for their support and funding for this project.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Stephen D. Roper1,2 and Nirupa Chaudhari Taste buds: cells, signals and synapses. Nat Rev Neurosci. 2017;18(8):485–497. DOI:10.1038/nrn.2017.68.
2. Ramanathan K, Antognini D, Combes A, Paden M, Zakhray B, Ogino M, MacLaren G, Brodie D, Shekar K. Planning and provision of ECMO services for severe ARDS during the COVID19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med;2020. Available:https://doi.org/10.1016/s2213-2600(20)30121-1.
3. Wu YC, Chen CS, Chan YJ (2020) Overview of the novel coronavirus (2019-nCoV): the pathogen of severe specific contagious pneumonia (SSCP). J Chin Med Assoc. Available:https://doi.org/10.1097/JCMA.0000000000000270.
4. Young BE, Ong SWX, Kalimuddin S et al Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA;2020. Available:https://doi.org/10.1001/jama.202 0.3204
5. Wan S, Xiang Y, Fang W, Zheng Y et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol;2020. Available: https://doi.org/10.1002/jmv.25783

6. Suzuki M, Saito K, Min WP, Vladau C, Toida K, Itoh H, Murakami S. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007;117(2):272–277.

7. Jerome R. Lechien et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. European Archives of Otorhinolaryngology. Available: https://doi.org/10.1007/s00405-020-05965-1

8. Cleaning and disinfection of environmental surfaces in the context of COVID-19: Interim guidance – WHO organization 15 th May 2020

9. L. Meng1, F. Hua2, and Z. Bian1. Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. Journal of Dental Research. 2020;99(5):481–487. DOI: 10.1177/0022034520914246.

10. Ibrahim Sayin, MD1, Kadiyre Kart Yasxar, MD2, and Zahide Mine Yazici, MD1 Taste and Smell Impairment in COVID-19: An AAO-HNS Anosmia Reporting ToolBased Comparative Study. Otolaryngology– Head and Neck Surgery 2020;1(7):1–7. DOI: 10.1177/019459820931820

11. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription polymerase chain reaction assay validated in vitro and with clinical specimens. J. Clin. Microbiol. 2020;58:e00310-20. DOI: 10.1128/JCM.00310-20

12. Chan JF, Yuan SF, Kok KH, To KK, Chu H, Yang J et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523. DOI: 10.1016/S0140-6736(20)30154-9

13. Chen HJ, Guo JJ, Wang C, Luo F, Yu X, Zhang PW et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809–815. DOI: 10.1016/S0140-6736(20)30360-3

14. Chen TM, Rui J, Wang QP, Zhao ZY, Cui JA, Yin LA. Mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infect. Dis. Poverty. 2020;9:24. Available: http://doi.org/10.1186/s40249-020-00640-3

15. China Center for Disease Control and Prevention; 2020. Available: http://2019ncov.chinacdc.cn/2019-nCoV/ (accessed March 30, 2020).

16. Christiane Matuschek, Friedrich Moll, Heiner Fangerau, Johannes C. Fischer, Kurt Zänker, Martijn van Griensven and Marion Schneider The history and value of face masks. Matuschek et al. Eur J Med Res. 2020;25:23. Available: https://doi.org/10.1186/s40001-020-00423-4

17. Ricky V. Tso and Benjamin J. Cowling. Importance of Face Masks for COVID-19: A Call for Effective Public Education. Clinical Infectious Diseases 2020;71(16):2195–8.

18. Seyed-Amir Tabatabaeizadeh. Airborne transmission of COVID-19 and the role of face mask to prevent it: a systematic review and meta-analysis. Tabatabaeizadeh Eur J Med Res. 2021;26:1. Available: https://doi.org/10.1186/s40001-020-00475-6

19. Centre for disease control and prevention (2021, May 13) Coronavirus comorbidities. Available: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

20. Hasan Ejaz, Abdullah Alsrhani, Aizza Zafar, Humera Javed, Kashaf Junaida, Abualgasim E. Abdela and Smell Impairment in COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health. 2020;13:1833–1839. Available: https://doi.org/10.1016/j.jiph.2020.07.014

21. Titus Sunday Ibekew, Ayotunde James Fasunla, and Adebola Emmanuel Orimadegun Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19. OTO Open 2020; 4(3):1–13. Available: http://doi.org/10.1177/2473974X20957975
22. Joaquim Mullol, Isam Alobid, Franklin Mariño-Sánchez, Adriana Izquierdo-Domínguez, Concepció Marin, Ludger Klimek et, al. The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. Curr Allergy Asthma Rep. 2020;20:61. Available: https://doi.org/10.1007/s11882-020-00961-1.

23. Timothée Klopfenstein, *, Hajer Zahrab, N’dri Juliette Kadiane-Oussoua, Quentin Lepiller, Pierre-Yves Royera, Lynda Toko. New loss of smell and taste: Uncommon symptoms in COVID-19 patients in Nord Franche-Comte cluster, France. / International Journal of Infectious Diseases. 2020;100:117–122. Available: https://doi.org/10.1016/j.ijid.2020.08.012.

24. Jonathan C. Kershaw and Richard D. Mattes. Nutrition and taste and smell dysfunction. World Journal of Otorhinolaryngology – Head and Neck. 2018;4:3–10.

25. Galya Bigman Age-related Smell and Taste Impairments and Vitamin D Associations in the U.S. Adults National Health and Nutrition Examination Survey. Nutrients. 2020;12(984):1–17. Available: https://doi:10.3390/nu12040984.